https://www.humanexa.io/ 2026-06-19T11:08:26.184Z daily 1 https://www.humanexa.io/pricing 2026-06-19T11:08:26.184Z weekly 0.95 https://www.humanexa.io/insights 2026-06-19T11:08:26.184Z weekly 0.9 https://www.humanexa.io/signals 2026-06-19T11:08:26.184Z weekly 0.9 https://www.humanexa.io/companies 2026-06-19T11:08:26.184Z weekly 0.88 https://www.humanexa.io/regulatory 2026-06-19T11:08:26.184Z weekly 0.9 https://www.humanexa.io/strategy 2026-06-19T11:08:26.184Z weekly 0.9 https://www.humanexa.io/simulations 2026-06-19T11:08:26.184Z weekly 0.9 https://www.humanexa.io/workspace 2026-06-19T11:08:26.184Z weekly 0.9 https://www.humanexa.io/welcome 2026-06-19T11:08:26.184Z weekly 0.9 https://www.humanexa.io/newsletter 2026-06-19T11:08:26.184Z weekly 0.85 https://www.humanexa.io/privacy 2026-06-19T11:08:26.184Z yearly 0.3 https://www.humanexa.io/terms 2026-06-19T11:08:26.184Z yearly 0.3 https://www.humanexa.io/contact 2026-06-19T11:08:26.184Z monthly 0.5 https://www.humanexa.io/century-of-biology 2026-06-19T11:08:26.184Z monthly 0.7 https://www.humanexa.io/bowtiedbiomed 2026-06-19T11:08:26.184Z monthly 0.7 https://www.humanexa.io/biotechtv 2026-06-19T11:08:26.184Z monthly 0.7 https://www.humanexa.io/decoding-bio 2026-06-19T11:08:26.184Z monthly 0.7 https://www.humanexa.io/asimov-press 2026-06-19T11:08:26.184Z monthly 0.7 https://www.humanexa.io/biotech-vector 2026-06-19T11:08:26.184Z monthly 0.7 https://www.humanexa.io/assets/emerging-combination-therapies-and-targeted-approaches-in-liver-cancer-treatment 2026-06-19T10:00:38.397Z weekly 0.88 https://www.humanexa.io/assets/imfinzi-and-imjudos-pfs-improvement-signals-competitive-shift-in-liver-cancer 2026-06-19T09:58:38.829Z weekly 0.88 https://www.humanexa.io/assets/braftovis-breakthrough-efficacy-positions-pfizer-for-market-leadership-in-mcrc 2026-06-19T09:58:29.604Z weekly 0.88 https://www.humanexa.io/assets/impact-of-adni4-on-alzheimers-drug-development-and-competitive-landscape 2026-06-19T09:56:54.623Z weekly 0.88 https://www.humanexa.io/assets/impax-labs-gains-competitive-edge-with-doxycycline-hyclate-approval 2026-06-19T09:53:11.913Z weekly 0.88 https://www.humanexa.io/assets/rivaroxabans-potential-shift-in-anticoagulation-strategy-for-hypertrophic-cardio 2026-06-19T08:51:39.198Z weekly 0.88 https://www.humanexa.io/assets/astrazenecas-ultomiris-shows-promise-in-igan-enhancing-nephrology-position 2026-06-19T08:51:34.673Z weekly 0.88 https://www.humanexa.io/assets/dinutuximabs-phase-iii-trial-could-redefine-neuroblastoma-treatment-standards 2026-06-19T08:48:11.329Z weekly 0.88 https://www.humanexa.io/assets/kshb002-trial-results-could-disrupt-orencias-market-position-in-ra 2026-06-19T08:46:37.834Z weekly 0.88 https://www.humanexa.io/assets/regulatory-developments-impacting-hypertension-and-glp-1-agonist-markets 2026-06-19T08:44:04.042Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-unique-dosing-approval-enhances-competitive-position-in-atopic-dermat 2026-06-19T08:41:19.071Z weekly 0.88 https://www.humanexa.io/assets/regulatory-developments-in-dermatology-implications-for-market-dynamics 2026-06-19T08:41:19.027Z weekly 0.88 https://www.humanexa.io/assets/zilovertamab-vedotins-phase-23-study-implications-for-rrdlbcl-treatment-landscap 2026-06-19T08:34:56.469Z weekly 0.88 https://www.humanexa.io/assets/kenvue-brands-strengthens-antihistamine-portfolio-with-zyrtec-hives-approval 2026-06-19T08:34:53.426Z weekly 0.88 https://www.humanexa.io/assets/roches-giredestrant-data-at-asco-2026-could-redefine-er-positive-breast-cancer-t 2026-06-19T08:33:01.458Z weekly 0.88 https://www.humanexa.io/assets/pridopidines-phase-3-trial-a-potential-breakthrough-in-als-treatment-landscape 2026-06-19T08:32:44.683Z weekly 0.88 https://www.humanexa.io/assets/regulatory-scrutiny-intensifies-for-abiomed-and-oscor-due-to-safety-concerns 2026-06-19T08:30:13.597Z weekly 0.88 https://www.humanexa.io/assets/medline-industries-catheter-recall-strategic-implications-for-cardiology-market 2026-06-19T08:30:13.289Z weekly 0.88 https://www.humanexa.io/assets/innovative-approaches-to-enhance-smoking-cessation-engagement-and-market-dynamic 2026-06-19T08:28:35.376Z weekly 0.88 https://www.humanexa.io/assets/emerging-competition-in-jak-inhibitors-apotexs-anda-submission-for-ruxolitinib 2026-06-19T08:26:31.348Z weekly 0.88 https://www.humanexa.io/assets/increased-competitive-pressure-in-antiepileptic-market-following-topiramate-subm 2026-06-19T08:25:59.811Z weekly 0.88 https://www.humanexa.io/assets/nih-biorepository-initiative-signals-shift-in-pulmonary-hypertension-landscape 2026-06-19T08:25:30.832Z weekly 0.88 https://www.humanexa.io/assets/genentechs-amd-study-could-reshape-treatment-strategies-and-market-dynamics 2026-06-19T08:25:26.835Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-aj1-11095-phase-1-data-enhances-competitive-position-in-myelofibrosis 2026-06-19T08:25:09.650Z weekly 0.88 https://www.humanexa.io/assets/duvakitugs-phase-3-study-initiation-strategic-implications-for-ulcerative-coliti 2026-06-19T08:24:42.842Z weekly 0.88 https://www.humanexa.io/assets/vitamin-ds-role-in-fertility-implications-for-womens-health-strategies 2026-06-19T08:24:27.888Z weekly 0.88 https://www.humanexa.io/assets/strategic-opportunities-in-ncrna-research-for-pancreatic-cancer-therapies 2026-06-19T08:24:25.554Z weekly 0.88 https://www.humanexa.io/assets/emerging-biomarkers-and-therapeutic-targets-in-oncology-strategic-implications 2026-06-19T08:24:24.610Z weekly 0.88 https://www.humanexa.io/assets/emerging-therapeutic-targets-in-oncology-stard10-pgccs-and-ncrnas 2026-06-19T08:23:43.558Z weekly 0.88 https://www.humanexa.io/assets/pfizers-berobenatide-phase-2b-results-position-it-as-a-market-leader-in-obesity 2026-06-19T08:22:50.560Z weekly 0.88 https://www.humanexa.io/assets/pfizers-berobenatide-and-emerging-competition-in-obesity-treatments 2026-06-19T08:22:50.402Z weekly 0.88 https://www.humanexa.io/assets/enhertus-potential-eu-approval-could-transform-her2-treatment-landscape 2026-06-19T08:02:42.520Z weekly 0.88 https://www.humanexa.io/assets/regulatory-developments-in-oncology-competitive-landscape-and-strategic-implicat 2026-06-19T08:02:42.428Z weekly 0.88 https://www.humanexa.io/assets/regulatory-developments-reshape-competitive-landscape-in-breast-cancer-therapies 2026-06-19T08:02:42.334Z weekly 0.88 https://www.humanexa.io/assets/impact-of-3d-printed-insoles-on-diabetic-neuropathy-treatment-landscape 2026-06-19T08:02:42.270Z weekly 0.88 https://www.humanexa.io/assets/emerging-imaging-alternatives-in-prostate-cancer-strategic-implications-for-nova 2026-06-19T08:02:26.392Z weekly 0.88 https://www.humanexa.io/assets/roches-ventana-pten-assay-approval-enhances-competitive-position-in-prostate-can 2026-06-19T08:02:17.232Z weekly 0.88 https://www.humanexa.io/assets/recent-fda-approvals-reshape-oncology-landscape-and-competitive-dynamics 2026-06-19T08:02:17.100Z weekly 0.88 https://www.humanexa.io/assets/tego-sciences-tpx-115-trial-a-potential-game-changer-in-orthopedic-regenerative- 2026-06-19T08:02:15.522Z weekly 0.88 https://www.humanexa.io/assets/emerging-opportunities-in-cytokine-modulation-and-adolescent-vaccination-strateg 2026-06-18T18:32:30.903Z weekly 0.88 https://www.humanexa.io/assets/emerging-vaccine-and-treatment-opportunities-in-influenza-and-respiratory-infect 2026-06-18T18:32:30.037Z weekly 0.88 https://www.humanexa.io/assets/regulatory-approvals-reshape-competitive-landscape-in-neurology-markets 2026-06-18T18:31:57.401Z weekly 0.88 https://www.humanexa.io/assets/regulatory-advances-in-neurology-implications-for-competitive-dynamics 2026-06-18T18:31:56.840Z weekly 0.88 https://www.humanexa.io/assets/aurobindo-pharmas-lamotrigine-approval-signals-market-disruption-in-antiepilepti 2026-06-18T18:31:27.225Z weekly 0.88 https://www.humanexa.io/assets/recent-fda-approvals-intensify-competition-in-neurology-market 2026-06-18T18:31:26.816Z weekly 0.88 https://www.humanexa.io/assets/upsher-smiths-deflazacort-approval-strengthens-competitive-position-in-corticost 2026-06-18T12:32:37.972Z weekly 0.88 https://www.humanexa.io/assets/regulatory-developments-reshape-competitive-landscape-in-immunology-market 2026-06-18T12:32:37.079Z weekly 0.88 https://www.humanexa.io/assets/regulatory-developments-in-immunology-strategic-implications-for-sle-treatments 2026-06-18T12:32:36.233Z weekly 0.88 https://www.humanexa.io/assets/alembics-anda-submission-for-bosutinib-competitive-dynamics-in-oncology-intensif 2026-06-18T12:32:04.572Z weekly 0.88 https://www.humanexa.io/assets/talzenna-and-xtandis-rpfs-improvement-sets-new-oncology-benchmark 2026-06-18T12:31:31.477Z weekly 0.88 https://www.humanexa.io/assets/comparative-effectiveness-study-on-ptsd-treatments-could-reshape-market-dynamics 2026-06-18T09:46:20.844Z weekly 0.88 https://www.humanexa.io/assets/emerging-clinical-trials-in-psychiatry-strategic-implications-for-weight-managem 2026-06-18T09:46:20.667Z weekly 0.88 https://www.humanexa.io/assets/fda-guidance-on-animal-testing-reshapes-oncology-drug-development-landscape 2026-06-18T08:04:32.466Z weekly 0.88 https://www.humanexa.io/assets/impact-of-alembics-tretinoin-approval-on-acne-treatment-market-dynamics 2026-06-18T08:04:04.807Z weekly 0.88 https://www.humanexa.io/assets/new-competitive-dynamics-in-contrast-agent-market-following-gadobutrol-approval 2026-06-18T08:03:58.782Z weekly 0.88 https://www.humanexa.io/assets/bayers-nda219627-approval-and-tevas-anda219413-submission-shift-competitive-dyna 2026-06-18T08:03:51.099Z weekly 0.88 https://www.humanexa.io/assets/emerging-lactylation-biomarker-enhances-melanoma-treatment-personalization 2026-06-18T08:02:48.465Z weekly 0.88 https://www.humanexa.io/assets/astrazenecas-revenue-growth-and-nme-readouts-strengthen-competitive-positioning 2026-06-18T00:33:19.770Z weekly 0.88 https://www.humanexa.io/assets/tevas-anda219413-submission-signals-potential-market-disruption 2026-06-18T00:32:54.406Z weekly 0.88 https://www.humanexa.io/assets/emerging-combination-therapies-redefining-melanoma-treatment-landscape 2026-06-18T00:32:26.273Z weekly 0.88 https://www.humanexa.io/assets/emerging-combination-therapies-reshape-melanoma-treatment-landscape 2026-06-18T00:32:25.077Z weekly 0.88 https://www.humanexa.io/assets/astrazenecas-imfinziimjudo-trial-results-enhance-competitive-position-in-liver-c 2026-06-18T00:32:12.159Z weekly 0.88 https://www.humanexa.io/assets/tezepelumabs-evolve-study-key-to-competitive-positioning-in-severe-asthma 2026-06-18T00:31:45.770Z weekly 0.88 https://www.humanexa.io/assets/strategic-implications-of-maridebart-cafraglutides-phase-3-trial-in-osa-manageme 2026-06-17T22:11:28.658Z weekly 0.88 https://www.humanexa.io/assets/mercks-keytruda-and-padcev-combination-strategic-regulatory-milestone-in-bladder 2026-06-17T22:09:54.594Z weekly 0.88 https://www.humanexa.io/assets/emerging-competition-in-ulcerative-colitis-boomerang-medicals-pivotal-trial-impa 2026-06-17T21:27:07.413Z weekly 0.88 https://www.humanexa.io/assets/emerging-rehabilitation-protocols-in-breast-cancer-surgery-strategic-implication 2026-06-17T18:32:29.957Z weekly 0.88 https://www.humanexa.io/assets/impact-of-clinical-trials-on-incontinence-associated-dermatitis-treatment-strate 2026-06-17T18:31:11.156Z weekly 0.88 https://www.humanexa.io/assets/durvalumabs-phase-iii-trial-could-transform-breast-cancer-treatment-landscape 2026-06-17T12:32:00.201Z weekly 0.88 https://www.humanexa.io/assets/cvs-caremark-coverage-enhances-eli-lillys-competitive-position-in-obesity-market 2026-06-17T12:21:18.145Z weekly 0.88 https://www.humanexa.io/assets/strategic-insights-on-als-immunotherapeutics-collaboration-and-regulatory-challe 2026-06-17T08:03:13.614Z weekly 0.88 https://www.humanexa.io/assets/strategic-implications-of-second-primary-cancer-risks-in-colorectal-cancer-survi 2026-06-17T08:03:03.528Z weekly 0.88 https://www.humanexa.io/assets/fda-approval-of-tzield-reshapes-pediatric-type-1-diabetes-treatment-landscape 2026-06-17T08:02:18.873Z weekly 0.88 https://www.humanexa.io/assets/impact-of-gut-microbiota-on-flutamide-efficacy-in-prostate-cancer-treatment 2026-06-17T08:02:10.076Z weekly 0.88 https://www.humanexa.io/assets/emerging-hydrogel-technology-disrupts-ocular-inflammation-treatment-landscape 2026-06-17T08:01:53.059Z weekly 0.88 https://www.humanexa.io/assets/strategic-implications-of-recent-regulatory-approvals-in-prostate-cancer 2026-06-17T08:01:09.069Z weekly 0.88 https://www.humanexa.io/assets/emerging-cd2-targeted-bispecific-antibodies-challenge-her2-t-cell-engagers 2026-06-17T06:33:39.160Z weekly 0.88 https://www.humanexa.io/assets/mercks-strategic-positioning-with-breakthrough-therapy-designation-for-calderasi 2026-06-17T06:30:59.972Z weekly 0.88 https://www.humanexa.io/assets/gsks-blu-5937-phase-3-trial-a-pivotal-moment-in-chronic-cough-treatment 2026-06-17T06:04:30.086Z weekly 0.88 https://www.humanexa.io/assets/roches-strategic-collaboration-to-enhance-leadership-in-b-cell-malignancies 2026-06-17T06:03:39.891Z weekly 0.88 https://www.humanexa.io/assets/mercks-enflonsia-approval-positions-it-as-leader-in-rsv-prevention-market 2026-06-17T06:03:02.736Z weekly 0.88 https://www.humanexa.io/assets/mercks-adc-strategy-faces-supply-chain-challenges-amid-daiichi-sankyo-update 2026-06-17T06:02:09.860Z weekly 0.88 https://www.humanexa.io/assets/strategic-implications-of-adc-advancements-in-breast-cancer-therapy 2026-06-17T00:31:24.802Z weekly 0.88 https://www.humanexa.io/assets/roches-vabysmo-and-susvimo-data-enhances-competitive-position-in-ophthalmology 2026-06-17T00:30:51.644Z weekly 0.88 https://www.humanexa.io/assets/pfizer-and-innovents-collaboration-enhances-oncology-pipeline-amid-competitive-p 2026-06-16T23:20:41.288Z weekly 0.88 https://www.humanexa.io/assets/eli-lilly-strengthens-infectious-disease-portfolio-through-strategic-acquisition 2026-06-16T23:20:00.461Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-foundayo-phase-3-success-redefines-type-2-diabetes-landscape 2026-06-16T23:17:12.456Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-retatrutide-emerges-as-a-game-changer-in-obesity-treatment-landscape 2026-06-16T22:58:41.041Z weekly 0.88 https://www.humanexa.io/assets/pfizers-hympavzi-approval-enhances-pediatric-hemophilia-treatment-landscape 2026-06-16T22:58:39.488Z weekly 0.88 https://www.humanexa.io/assets/nanomaterial-based-vaccines-a-disruptive-innovation-in-rotavirus-protection 2026-06-16T22:57:04.582Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-retatrutide-phase-3-success-reinforces-competitive-position-in-obesit 2026-06-16T22:54:37.198Z weekly 0.88 https://www.humanexa.io/assets/mercks-oral-pcsk9-inhibitor-development-enhances-competitive-positioning 2026-06-16T18:31:39.216Z weekly 0.88 https://www.humanexa.io/assets/strategic-implications-of-sal0140s-phase-ii-trial-in-primary-aldosteronism 2026-06-16T18:31:34.906Z weekly 0.88 https://www.humanexa.io/assets/lillys-foundayo-emerges-as-a-strong-contender-in-obesity-treatment-market 2026-06-16T12:32:44.129Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-verve-102-a-potential-game-changer-in-cardiovascular-gene-editing 2026-06-16T12:31:55.380Z weekly 0.88 https://www.humanexa.io/assets/mercks-keytruda-gains-competitive-edge-in-melanoma-with-promising-data 2026-06-16T12:31:44.310Z weekly 0.88 https://www.humanexa.io/assets/roches-strategic-partnership-enhances-position-in-b-cell-malignancies-market 2026-06-16T08:02:20.682Z weekly 0.88 https://www.humanexa.io/assets/roches-tecentriq-faces-critical-regulatory-decision-for-stage-iii-colon-cancer 2026-06-16T08:01:17.552Z weekly 0.88 https://www.humanexa.io/assets/roches-liver-disease-panel-launch-sets-new-standard-in-hepatology-diagnostics 2026-06-16T06:35:04.285Z weekly 0.88 https://www.humanexa.io/assets/enhertus-eu-approval-could-redefine-her2-treatment-landscape 2026-06-16T06:35:04.106Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-retevmo-faces-competitive-pressure-ahead-of-asco-2026-presentation 2026-06-16T06:32:29.168Z weekly 0.88 https://www.humanexa.io/assets/imfinzis-promising-trial-results-enhance-competitive-position-in-bladder-cancer 2026-06-16T06:31:59.252Z weekly 0.88 https://www.humanexa.io/assets/gilead-and-mercks-islatravirlenacapavir-phase-3-success-signals-market-disruptio 2026-06-16T06:31:56.570Z weekly 0.88 https://www.humanexa.io/assets/tozorakimabs-phase-iii-success-positions-astrazeneca-for-copd-leadership 2026-06-16T06:05:25.270Z weekly 0.88 https://www.humanexa.io/assets/lillys-zepbound-launch-strategic-positioning-in-obstructive-sleep-apnea-market 2026-06-15T11:55:20.853Z weekly 0.88 https://www.humanexa.io/assets/digital-innovations-in-depression-treatment-a-potential-paradigm-shift 2026-06-14T19:05:15.555Z weekly 0.88 https://www.humanexa.io/assets/innovative-behavioral-and-digital-interventions-transforming-mental-health-care- 2026-06-14T19:05:15.181Z weekly 0.88 https://www.humanexa.io/assets/strategic-implications-of-new-melanoma-biobank-for-research-and-development 2026-06-14T19:05:10.487Z weekly 0.88 https://www.humanexa.io/assets/covac-2-vaccine-emerges-as-competitive-booster-option-in-resource-limited-settin 2026-06-14T19:03:58.293Z weekly 0.88 https://www.humanexa.io/assets/enhancing-catheterization-protocols-for-obese-icu-patients-through-ultrasound-gu 2026-06-14T19:03:19.479Z weekly 0.88 https://www.humanexa.io/assets/cu-20101-phase-3-trial-poses-significant-threat-to-botox-market-share 2026-06-13T08:00:56.069Z weekly 0.88 https://www.humanexa.io/assets/impact-of-midazolam-timing-study-on-pediatric-anesthesia-practices 2026-06-12T08:01:24.133Z weekly 0.88 https://www.humanexa.io/assets/advancements-in-drug-delivery-for-cns-infections-strategic-implications-for-amph 2026-06-11T18:01:56.418Z weekly 0.88 https://www.humanexa.io/assets/cxds-ketogenic-diet-trial-a-potential-game-changer-in-masld-treatment 2026-06-11T12:01:31.291Z weekly 0.88 https://www.humanexa.io/assets/astrazenecas-baxfendy-approval-a-strategic-shift-in-hypertension-treatment 2026-06-11T09:12:14.605Z weekly 0.88 https://www.humanexa.io/assets/microbiome-targeted-nutrition-study-could-transform-type-2-diabetes-management 2026-06-11T08:01:01.059Z weekly 0.88 https://www.humanexa.io/assets/fda-clearance-of-bridge-device-signals-regulatory-shift-in-oud-treatment-landsca 2026-06-11T06:01:36.623Z weekly 0.88 https://www.humanexa.io/assets/torrent-pharmaceuticals-gains-competitive-edge-with-lurasidone-hydrochloride-app 2026-06-10T06:00:36.878Z weekly 0.88 https://www.humanexa.io/assets/baxters-phenylephrine-approval-reshapes-vasopressor-market-dynamics 2026-06-10T04:54:09.378Z weekly 0.88 https://www.humanexa.io/assets/regulatory-approvals-reshape-competitive-landscape-in-cardiovascular-market 2026-06-10T04:54:09.282Z weekly 0.88 https://www.humanexa.io/assets/hospiras-lidocaine-approval-enhances-competitive-position-in-pain-management 2026-06-10T02:31:56.762Z weekly 0.88 https://www.humanexa.io/assets/micro-labs-generic-approval-disrupts-hypertension-market-dynamics 2026-06-10T02:25:08.529Z weekly 0.88 https://www.humanexa.io/assets/regulatory-milestone-for-traveres-filspari-enhances-competitive-positioning 2026-06-10T00:01:50.614Z weekly 0.88 https://www.humanexa.io/assets/strategic-engagement-essential-for-dual-prevention-pill-market-success 2026-06-08T02:28:01.220Z weekly 0.88 https://www.humanexa.io/assets/regulatory-acceptance-of-cosopt-pf-signals-competitive-shift-in-glaucoma-market 2026-06-07T06:01:37.909Z weekly 0.88 https://www.humanexa.io/assets/emerging-anesthetic-techniques-and-opioid-sparing-strategies-in-pain-management 2026-06-06T18:54:33.969Z weekly 0.88 https://www.humanexa.io/assets/emerging-therapeutics-in-copd-tozorakimab-and-nmes-trials-signal-strategic-shift 2026-06-06T14:54:00.106Z weekly 0.88 https://www.humanexa.io/assets/tozorakimabs-phase-iii-success-positions-it-as-a-leader-in-copd-treatment 2026-06-06T14:54:00.053Z weekly 0.88 https://www.humanexa.io/assets/jiangsu-hansohs-dapagliflozin-submission-intensifies-sglt2-inhibitor-competition 2026-06-06T08:00:28.047Z weekly 0.88 https://www.humanexa.io/assets/regulatory-developments-enhance-competitive-landscape-for-tyvaso-in-pah-market 2026-06-06T08:00:21.796Z weekly 0.88 https://www.humanexa.io/assets/positive-phase-iii-results-for-efzimfotase-alfa-reshape-hypophosphatasia-landsca 2026-06-03T01:14:22.460Z weekly 0.88 https://www.humanexa.io/assets/breztris-unique-positioning-as-first-triple-therapy-in-asthma-market 2026-06-03T01:14:21.674Z weekly 0.88 https://www.humanexa.io/assets/navigating-new-fda-guidance-on-pregnancy-safety-studies-in-drug-development 2026-06-03T01:14:21.514Z weekly 0.88 https://www.humanexa.io/signals/tebentafusp-establishes-first-line-treatment-for-hla-a0201-positive-uveal-melano 2026-06-17T06:32:42.643Z weekly 0.8 https://www.humanexa.io/signals/mercks-enflonsia-approved-in-eu-for-rsv-prevention-in-infants 2026-06-17T06:02:41.035Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-roches-gazyva-for-systemic-lupus-erythematosus-treatment 2026-06-17T06:01:58.624Z weekly 0.8 https://www.humanexa.io/signals/roches-enspryng-shows-68-relapse-reduction-in-phase-iii-mogad-study 2026-06-17T06:01:48.623Z weekly 0.8 https://www.humanexa.io/signals/roches-elecsys-ptau217-blood-test-receives-ce-mark-for-alzheimers-diagnosis 2026-06-16T12:30:48.590Z weekly 0.8 https://www.humanexa.io/signals/fda-odac-recommends-truqap-for-pten-deficient-prostate-cancer 2026-06-16T06:32:32.027Z weekly 0.8 https://www.humanexa.io/signals/datroway-approved-in-us-as-first-trop2-directed-adc-for-1l-triple-negative-breas 2026-06-16T06:31:51.490Z weekly 0.8 https://www.humanexa.io/signals/pfizers-lorbrena-crown-trial-reports-longest-progression-free-survival-in-advanc 2026-06-16T06:02:51.045Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-nda-for-roches-giredestrant-in-early-stage-er-positive-breast-cancer-1 2026-06-16T06:02:19.790Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-nda-for-roches-giredestrant-in-early-stage-er-positive-breast-cancer 2026-06-16T06:02:04.190Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-priority-review-for-roches-tecentriq-in-stage-iii-colon-cancer-1 2026-06-11T12:01:11.515Z weekly 0.8 https://www.humanexa.io/signals/abiomed-and-oscor-warn-of-catheter-introducer-leakage-risk 2026-06-19T06:32:21.275Z weekly 0.8 https://www.humanexa.io/signals/medline-industries-expands-catheter-recall-due-to-infection-risk 2026-06-19T06:03:43.994Z weekly 0.8 https://www.humanexa.io/signals/amgens-xaluritamig-plus-abiraterone-trial-targets-metastatic-prostate-cancer 2026-06-19T06:02:48.695Z weekly 0.8 https://www.humanexa.io/signals/phase-ii-trial-of-ildr-plus-immunochemotherapy-in-borderline-resectable-esophage 2026-06-19T06:02:29.586Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-early-treatment-in-high-risk-cllsll-shows-promise 2026-06-19T06:02:16.670Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-capvaxive-for-at-risk-children-and-adolescents 2026-06-19T06:01:28.898Z weekly 0.8 https://www.humanexa.io/signals/study-on-frailty-in-young-adult-survivors-of-childhood-cancer-highlights-long-te 2026-06-18T18:30:48.763Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-priority-review-for-keytruda-qlex-supplement-application 2026-06-18T12:32:05.698Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-priority-review-for-welireg-supplement-nda215383 2026-06-18T12:31:16.329Z weekly 0.8 https://www.humanexa.io/signals/digital-management-improves-outcomes-in-early-cardiogenic-shock-patients 2026-06-18T06:31:44.454Z weekly 0.8 https://www.humanexa.io/signals/combomatch-trial-targets-genetic-mutations-in-advanced-solid-tumors 2026-06-18T06:03:48.680Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-nivolumab-post-surgery-in-non-small-cell-lung-cancer 2026-06-18T06:03:26.687Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-atezolizumab-with-chemotherapy-for-metastatic-colorectal-canc 2026-06-18T06:03:14.628Z weekly 0.8 https://www.humanexa.io/signals/trial-comparing-radiotherapy-with-dual-immunotherapy-in-locally-advanced-rectal- 2026-06-18T06:02:58.138Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-pembrolizumab-plus-doxorubicin-in-aggressive-sarcomas 2026-06-18T06:02:32.869Z weekly 0.8 https://www.humanexa.io/signals/sintilimab-and-ipilimumab-show-promise-in-first-line-therapy-for-advanced-biliar 2026-06-18T06:02:17.512Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-application-for-baxfendy-baxdrostat-from-astrazeneca 2026-06-18T00:31:52.115Z weekly 0.8 https://www.humanexa.io/signals/cardiff-oncology-and-pfizer-assess-onvansertib-in-metastatic-colorectal-cancer-t 2026-06-18T00:31:00.828Z weekly 0.8 https://www.humanexa.io/signals/fda-proposes-exclusion-of-semaglutide-tirzepatide-and-liraglutide-from-503b-bulk 2026-06-17T18:32:32.154Z weekly 0.8 https://www.humanexa.io/signals/norm-hf-study-to-evaluate-fire1-norm-system-in-heart-failure-management 2026-06-17T18:31:28.597Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-supplement-for-inqovi-nda-212576-by-taiho-oncology 2026-06-17T12:32:12.732Z weekly 0.8 https://www.humanexa.io/signals/stard10s-role-in-her2-breast-cancer-progression-and-lipid-metabolism 2026-06-17T12:32:03.447Z weekly 0.8 https://www.humanexa.io/signals/otac-trial-evaluates-anti-covid-19-immunoglobulin-in-outpatients 2026-06-17T12:31:53.003Z weekly 0.8 https://www.humanexa.io/signals/polyploid-giant-cancer-cells-drive-aggressiveness-in-ovarian-cancer-and-indicate 2026-06-17T06:34:16.574Z weekly 0.8 https://www.humanexa.io/signals/lactylation-related-biomarker-predicts-prognosis-and-therapy-response-in-cutaneo 2026-06-17T06:34:03.216Z weekly 0.8 https://www.humanexa.io/signals/novel-pra-peptide-hydrogel-shows-promise-for-treating-ocular-inflammation 2026-06-17T06:33:48.630Z weekly 0.8 https://www.humanexa.io/signals/gut-microbiota-impairs-flutamide-efficacy-in-prostate-cancer-treatment 2026-06-17T06:33:35.927Z weekly 0.8 https://www.humanexa.io/signals/gene-amplification-adjacent-to-f3-linked-to-poor-outcomes-in-pancreatic-adenocar 2026-06-17T06:33:10.613Z weekly 0.8 https://www.humanexa.io/signals/e7-mrnalnp-vaccine-shows-promise-in-treating-early-stage-hpv-tumors-in-mice 2026-06-17T06:32:59.505Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-pembrolizumab-with-chemotherapy-in-non-small-cell-lung-cancer 2026-06-17T06:32:05.835Z weekly 0.8 https://www.humanexa.io/signals/phase-3-study-of-l606-in-patients-with-ph-ild-shows-safety-and-efficacy-potentia 2026-06-17T06:31:45.014Z weekly 0.8 https://www.humanexa.io/signals/phase-3-trial-of-orelabrutinib-in-secondary-progressive-ms-underway 2026-06-17T06:31:22.792Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-herceptin-hylecta-or-phesgo-with-chemotherapy-for-her2-positi 2026-06-17T06:31:10.984Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-medi5752-in-unresectable-pleural-mesothelioma-launched 2026-06-17T06:30:57.596Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-giredestrant-vs-endocrine-therapy-in-er-her2-early-breast-can 2026-06-17T06:30:43.569Z weekly 0.8 https://www.humanexa.io/signals/ifinatamab-deruxtecan-receives-priority-review-for-es-sclc-in-the-us 2026-06-17T06:30:25.574Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-study-of-durvalumab-domvanalimab-in-stage-iii-unresectable-nsclc-initi 2026-06-17T06:04:40.353Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-evaluates-cemiplimab-with-surgery-for-advanced-skin-cancer 2026-06-17T06:04:29.780Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-osimertinib-and-bevacizumab-in-egfr-mutant-lung-cancer 2026-06-17T06:04:08.143Z weekly 0.8 https://www.humanexa.io/signals/phase-3-study-of-blu-5937-shows-promise-for-refractory-chronic-cough 2026-06-17T06:03:58.365Z weekly 0.8 https://www.humanexa.io/signals/acadia-pharmaceuticals-initiates-acp-204-trials-for-alzheimers-disease-psychosis 2026-06-17T06:03:48.692Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-syha1813-shows-promise-for-high-grade-meningiomas 2026-06-17T06:03:39.485Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-dinutuximab-in-high-risk-neuroblastoma-shows-promise 2026-06-17T06:03:28.190Z weekly 0.8 https://www.humanexa.io/signals/pfizers-phase-3-study-of-tofacitinib-in-pediatric-ulcerative-colitis-underway 2026-06-17T06:03:15.654Z weekly 0.8 https://www.humanexa.io/signals/mercks-acquisition-of-terns-pharmaceuticals-advances-as-hsr-waiting-period-expir 2026-06-17T06:03:03.342Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-priority-review-for-keytruda-and-keytruda-qlex-in-mibc-treatment 2026-06-17T06:02:30.307Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-mercks-idvynso-for-virologically-suppressed-hiv-1-patients 2026-06-17T06:02:20.733Z weekly 0.8 https://www.humanexa.io/signals/merck-and-eisais-litespark-012-trial-fails-to-meet-primary-endpoints-in-rcc 2026-06-17T06:02:08.432Z weekly 0.8 https://www.humanexa.io/signals/roche-reports-strong-q1-2026-sales-growth-driven-by-innovative-medicines-and-dia 2026-06-17T06:01:38.319Z weekly 0.8 https://www.humanexa.io/signals/mrna-1083-shows-durable-immune-response-and-safety-in-adults-50-years 2026-06-17T00:32:17.258Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-durvalumab-with-chemotherapy-in-stage-ii-iii-breast-cancer 2026-06-17T00:32:07.341Z weekly 0.8 https://www.humanexa.io/signals/calderasib-and-pembrolizumab-study-in-kras-g12c-nsclc-shows-promising-efficacy 2026-06-17T00:31:39.582Z weekly 0.8 https://www.humanexa.io/signals/neoadjuvant-therapy-trial-for-tnbc-sacituzumab-govitecan-pembrolizumab 2026-06-17T00:31:21.789Z weekly 0.8 https://www.humanexa.io/signals/overview-of-antibody-drug-conjugates-in-cancer-therapy-and-clinical-development 2026-06-17T00:31:04.371Z weekly 0.8 https://www.humanexa.io/signals/merck-acquires-terns-pharmaceuticals-enhancing-oncology-pipeline-with-tern-701 2026-06-17T00:30:54.395Z weekly 0.8 https://www.humanexa.io/signals/merck-receives-fda-approval-for-idvynso-expands-oncology-pipeline-and-animal-hea 2026-06-17T00:30:43.182Z weekly 0.8 https://www.humanexa.io/signals/roche-presents-new-data-on-vabysmo-and-susvimo-at-arvo-2026 2026-06-17T00:30:34.270Z weekly 0.8 https://www.humanexa.io/signals/pfizers-elrexfio-shows-significant-pfs-improvement-in-rrmm-patients 2026-06-17T00:30:23.482Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-bizengri-for-nrg1-fusion-positive-cholangiocarcinoma 2026-06-16T18:32:38.060Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-tzield-for-pediatric-patients-with-stage-3-type-1-diabetes 2026-06-16T18:32:23.118Z weekly 0.8 https://www.humanexa.io/signals/cmp-001-and-nivolumab-show-promise-in-advanced-melanoma-phase-23-trial 2026-06-16T18:32:12.027Z weekly 0.8 https://www.humanexa.io/signals/ashwagen-shows-efficacy-in-managing-stress-and-anxiety-in-hypertensive-patients 2026-06-16T18:32:02.988Z weekly 0.8 https://www.humanexa.io/signals/fda-odac-vote-against-camizestrant-for-hr-positive-breast-cancer-raises-concerns 2026-06-16T18:31:42.702Z weekly 0.8 https://www.humanexa.io/signals/merck-publishes-method-for-scalable-synthesis-of-oral-pcsk9-inhibitor-enlicitide 2026-06-16T18:31:14.327Z weekly 0.8 https://www.humanexa.io/signals/roche-to-acquire-pathai-for-750m-to-enhance-ai-driven-diagnostics-1 2026-06-16T18:30:53.801Z weekly 0.8 https://www.humanexa.io/signals/roche-to-acquire-pathai-for-750m-to-enhance-ai-driven-diagnostics 2026-06-16T18:30:44.179Z weekly 0.8 https://www.humanexa.io/signals/cvs-caremark-to-cover-foundayo-and-zepbound-enhancing-access-for-obesity-treatme 2026-06-16T12:32:38.624Z weekly 0.8 https://www.humanexa.io/signals/lilly-expands-infectious-disease-portfolio-with-three-strategic-acquisitions 2026-06-16T12:32:28.752Z weekly 0.8 https://www.humanexa.io/signals/lillys-foundayo-shows-significant-weight-loss-in-menopausal-women 2026-06-16T12:32:20.769Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-lillys-ebglyss-for-atopic-dermatitis-with-unique-dosing-regimen 2026-06-16T12:32:11.906Z weekly 0.8 https://www.humanexa.io/signals/nextcove-trial-shows-mrna-1283-vaccine-elicits-higher-nab-responses-than-mrna-12 2026-06-16T12:31:49.891Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-breakthrough-therapy-designation-for-calderasib-in-kras-g12c-mutant-n 2026-06-16T12:31:41.859Z weekly 0.8 https://www.humanexa.io/signals/lillys-verve-102-shows-significant-ldl-c-reduction-in-phase-1b-trial 2026-06-16T12:31:32.802Z weekly 0.8 https://www.humanexa.io/signals/merck-reports-promising-long-term-data-for-keytruda-and-intismeran-in-oncology-a 2026-06-16T12:31:23.265Z weekly 0.8 https://www.humanexa.io/signals/saphnelo-self-administration-approved-in-the-us-for-sle-treatment 2026-06-16T12:31:14.113Z weekly 0.8 https://www.humanexa.io/signals/roches-elecsys-ptau217-blood-test-receives-ce-mark-for-alzheimers-detection 2026-06-16T12:31:01.005Z weekly 0.8 https://www.humanexa.io/signals/european-commission-approves-pfizers-hympavzi-for-hemophilia-a-and-b-treatment 2026-06-16T12:30:40.597Z weekly 0.8 https://www.humanexa.io/signals/roche-launches-liver-disease-panel-to-enhance-chronic-liver-disease-management 2026-06-16T06:34:06.112Z weekly 0.8 https://www.humanexa.io/signals/lillys-foundayo-shows-superior-a1c-reduction-and-weight-loss-in-pivotal-diabetes 2026-06-16T06:33:56.091Z weekly 0.8 https://www.humanexa.io/signals/truqap-approved-in-us-for-pten-deficient-metastatic-prostate-cancer 2026-06-16T06:33:46.468Z weekly 0.8 https://www.humanexa.io/signals/5-year-data-shows-intismeran-autogene-keytruda-reduces-melanoma-recurrence-risk- 2026-06-16T06:33:24.794Z weekly 0.8 https://www.humanexa.io/signals/lillys-retevmo-shows-83-reduction-in-disease-recurrence-for-early-stage-ret-fusi 2026-06-16T06:33:12.517Z weekly 0.8 https://www.humanexa.io/signals/lillys-foundayo-shows-superior-results-in-phase-3-trial-for-type-2-diabetes 2026-06-16T06:33:02.524Z weekly 0.8 https://www.humanexa.io/signals/imfinzi-gains-us-approval-for-early-bladder-cancer-with-bcg-combination 2026-06-16T06:32:53.274Z weekly 0.8 https://www.humanexa.io/signals/enhertu-gains-fda-approval-for-two-new-her2-early-breast-cancer-indications 2026-06-16T06:32:44.404Z weekly 0.8 https://www.humanexa.io/signals/foundayo-shows-significant-weight-reduction-in-older-adults-with-obesity-in-new- 2026-06-16T06:32:22.100Z weekly 0.8 https://www.humanexa.io/signals/lilly-to-present-phase-3-study-of-retevmo-in-ret-fusion-positive-nsclc-at-asco-2 2026-06-16T06:32:11.973Z weekly 0.8 https://www.humanexa.io/signals/lillys-retatrutide-shows-significant-weight-loss-in-phase-3-obesity-trial 2026-06-16T06:32:01.949Z weekly 0.8 https://www.humanexa.io/signals/gilead-and-merck-report-positive-phase-3-results-for-once-weekly-hiv-treatment-i 2026-06-16T06:31:41.775Z weekly 0.8 https://www.humanexa.io/signals/imfinzi-ev-shows-significant-survival-benefits-in-muscle-invasive-bladder-cancer 2026-06-16T06:31:31.676Z weekly 0.8 https://www.humanexa.io/signals/roche-advances-obesity-portfolio-with-promising-phase-ii-data-on-enicepatide-and 2026-06-16T06:31:22.496Z weekly 0.8 https://www.humanexa.io/signals/roche-advances-obesity-portfolio-with-promising-phase-ii-data-for-enicepatide-an 2026-06-16T06:31:11.369Z weekly 0.8 https://www.humanexa.io/signals/camizestrant-recommended-for-1st-line-er-positive-breast-cancer-in-eu 2026-06-16T06:31:00.877Z weekly 0.8 https://www.humanexa.io/signals/mercks-keytruda-plus-padcev-receives-positive-eu-chmp-opinion-for-muscle-invasiv 2026-06-16T06:30:51.981Z weekly 0.8 https://www.humanexa.io/signals/mercks-sacituzumab-tirumotecan-shows-os-and-pfs-improvement-in-endometrial-cance 2026-06-16T06:30:40.934Z weekly 0.8 https://www.humanexa.io/signals/roche-and-nurix-collaborate-on-btk-degrader-bexobrutideg-for-b-cell-malignancies-1 2026-06-16T06:05:30.126Z weekly 0.8 https://www.humanexa.io/signals/roche-and-nurix-collaborate-on-btk-degrader-bexobrutideg-for-b-cell-malignancies 2026-06-16T06:05:14.101Z weekly 0.8 https://www.humanexa.io/signals/tozorakimab-shows-positive-phase-iii-results-in-copd-reducing-exacerbations 2026-06-16T06:04:57.466Z weekly 0.8 https://www.humanexa.io/signals/ultomiris-meets-primary-endpoint-in-phase-iii-trial-for-igan 2026-06-16T06:04:42.021Z weekly 0.8 https://www.humanexa.io/signals/merck-and-gilead-discontinue-phase-3-study-of-trodelvy-and-keytruda-in-nsclc 2026-06-16T06:04:26.877Z weekly 0.8 https://www.humanexa.io/signals/pfizers-25vpnc-vaccine-shows-strong-phase-2-results-advancing-to-phase-3 2026-06-16T06:04:11.835Z weekly 0.8 https://www.humanexa.io/signals/pfizer-and-innovent-collaborate-on-12-early-stage-oncology-programs 2026-06-16T06:03:56.766Z weekly 0.8 https://www.humanexa.io/signals/pfizers-berobenatide-shows-promising-phase-2b-results-for-monthly-dosing-in-obes 2026-06-16T06:03:42.162Z weekly 0.8 https://www.humanexa.io/signals/roche-to-present-promising-giredestrant-data-at-asco-2026-for-early-breast-cance-1 2026-06-16T06:03:28.576Z weekly 0.8 https://www.humanexa.io/signals/roche-to-present-promising-giredestrant-data-at-asco-2026-for-early-breast-cance 2026-06-16T06:03:06.243Z weekly 0.8 https://www.humanexa.io/signals/talzenna-plus-xtandi-shows-52-rpfs-improvement-in-metastatic-prostate-cancer 2026-06-16T06:02:35.354Z weekly 0.8 https://www.humanexa.io/signals/pfizers-braftovi-regimen-nearly-doubles-progression-free-survival-in-mcrc 2026-06-16T06:01:50.639Z weekly 0.8 https://www.humanexa.io/signals/nanomaterial-based-vaccines-show-promise-for-improved-rotavirus-protection 2026-06-15T11:55:36.199Z weekly 0.8 https://www.humanexa.io/signals/novel-cd2-targeted-bispecific-antibody-enhances-t-cell-engagers-for-solid-tumors 2026-06-15T11:55:27.900Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-tr115-vs-investigators-choice-in-relapsedrefractory-periphera 2026-06-15T11:54:45.509Z weekly 0.8 https://www.humanexa.io/signals/lillys-jaypirca-shows-45-reduction-in-disease-progression-risk-in-cllsll 2026-06-15T11:54:28.604Z weekly 0.8 https://www.humanexa.io/signals/lilly-presents-promising-phase-1-data-for-first-in-class-type-ii-jak2-inhibitor- 2026-06-14T12:00:27.358Z weekly 0.8 https://www.humanexa.io/signals/rivaroxaban-trial-for-antithrombotic-prevention-in-hypertrophic-cardiomyopathy-p 2026-06-14T06:00:18.632Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-keytruda-combinations-for-adjuvant-treatment-in-clear-cell-rcc 2026-06-13T12:00:46.215Z weekly 0.8 https://www.humanexa.io/signals/roches-ventana-pten-assay-receives-fda-approval-for-prostate-cancer-companion-di 2026-06-13T12:00:20.007Z weekly 0.8 https://www.humanexa.io/signals/phase-3-study-of-cu-20101-shows-promise-for-glabellar-lines-compared-to-botox 2026-06-13T00:00:45.698Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-priority-review-for-roches-tecentriq-in-stage-iii-colon-cancer 2026-06-11T12:00:57.741Z weekly 0.8 https://www.humanexa.io/signals/fda-clears-bridge-device-for-opioid-use-disorder-treatment-efficacy-under-evalua 2026-06-11T06:01:16.361Z weekly 0.8 https://www.humanexa.io/signals/pridopidine-phase-3-trial-initiated-for-als-efficacy-and-safety-evaluation 2026-06-10T18:00:32.582Z weekly 0.8 https://www.humanexa.io/signals/lipus-and-microbubbles-enhance-amphotericin-b-delivery-for-cryptococcal-meningit 2026-06-10T12:01:18.493Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-pfizers-hympavzi-for-expanded-hemophilia-a-and-b-indications 2026-06-10T12:00:41.077Z weekly 0.8 https://www.humanexa.io/signals/lillys-retatrutide-shows-significant-weight-loss-and-pain-reduction-in-triumph-1 2026-06-07T06:01:53.253Z weekly 0.8 https://www.humanexa.io/signals/study-on-cardiovascular-abnormalities-in-children-with-adhd-launched 2026-06-19T06:32:11.972Z weekly 0.8 https://www.humanexa.io/signals/study-on-cardiac-rehabilitation-in-hypertensive-rheumatoid-arthritis-patients-in 2026-06-19T06:32:03.401Z weekly 0.8 https://www.humanexa.io/signals/abbvie-initiates-trial-for-abbv-932-in-bipolar-disorder-depressive-episodes 2026-06-19T06:31:55.507Z weekly 0.8 https://www.humanexa.io/signals/crlx101-and-paclitaxel-combination-study-in-ovarian-cancer-initiated-by-newlink- 2026-06-19T06:31:45.616Z weekly 0.8 https://www.humanexa.io/signals/nci-launches-study-on-natural-history-of-cns-tumors-to-enhance-treatment-options 2026-06-19T06:30:56.542Z weekly 0.8 https://www.humanexa.io/signals/study-on-yanjiu-needle-for-pharyngeal-dysphagia-shows-promise-in-stroke-patients 2026-06-19T06:30:48.351Z weekly 0.8 https://www.humanexa.io/signals/abbvie-evaluates-xen63-gel-stent-for-glaucoma-via-two-surgical-approaches 2026-06-19T06:30:40.102Z weekly 0.8 https://www.humanexa.io/signals/tego-science-initiates-study-on-tpx-115-for-partial-thickness-rotator-cuff-tear 2026-06-19T06:03:27.923Z weekly 0.8 https://www.humanexa.io/signals/astrazeneca-leads-study-on-dlbcl-treatment-patterns-in-mea-region 2026-06-19T06:03:13.111Z weekly 0.8 https://www.humanexa.io/signals/edinburgh-study-investigates-pancreas-lipotoxicity-and-weight-loss-in-type-2-dia 2026-06-19T06:03:01.487Z weekly 0.8 https://www.humanexa.io/signals/establishment-of-pulmonary-hypertension-biorepository-for-future-biomarker-disco 2026-06-19T06:02:37.962Z weekly 0.8 https://www.humanexa.io/signals/pilot-trial-to-assess-cognitive-function-changes-in-rett-syndrome-during-trofine 2026-06-19T06:02:05.628Z weekly 0.8 https://www.humanexa.io/signals/fruquintinib-study-in-metastatic-colorectal-cancer-patients-in-poland 2026-06-19T06:01:53.724Z weekly 0.8 https://www.humanexa.io/signals/phase-2-study-of-chidamide-for-mrd-positive-dlbcl-in-first-complete-remission 2026-06-19T06:01:39.472Z weekly 0.8 https://www.humanexa.io/signals/first-in-human-study-of-ntsr1-targeted-imaging-in-prostate-cancer-shows-promise 2026-06-18T18:32:35.963Z weekly 0.8 https://www.humanexa.io/signals/risdiplam-study-to-assess-real-world-outcomes-in-type-i-and-ii-sma 2026-06-18T18:32:17.644Z weekly 0.8 https://www.humanexa.io/signals/biogens-felzartamab-study-targets-immunoglobulin-a-nephropathy-in-adults 2026-06-18T18:32:08.481Z weekly 0.8 https://www.humanexa.io/signals/trial-evaluates-dispepril-efficacy-in-functional-dyspepsia-vs-proton-pump-inhibi 2026-06-18T18:31:58.881Z weekly 0.8 https://www.humanexa.io/signals/pilot-study-on-text-based-contingency-management-for-smoking-cessation-engagemen 2026-06-18T18:31:42.649Z weekly 0.8 https://www.humanexa.io/signals/decipheras-vimseltinib-study-evaluates-interaction-with-oral-contraceptives 2026-06-18T18:31:30.133Z weekly 0.8 https://www.humanexa.io/signals/st-judes-protocol-for-long-term-review-of-childhood-cancer-survivors 2026-06-18T18:31:19.124Z weekly 0.8 https://www.humanexa.io/signals/study-on-riociguats-impact-on-right-heart-function-in-pah-and-cteph 2026-06-18T18:31:09.487Z weekly 0.8 https://www.humanexa.io/signals/study-on-host-pathogen-interaction-with-staphylococcus-aureus-using-lymphoid-org 2026-06-18T18:31:00.412Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-supplemental-application-for-rextovy-by-amphastar-pharmaceuticals 2026-06-18T18:30:40.003Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-approval-for-lacosamide-anda217596 2026-06-18T18:30:31.293Z weekly 0.8 https://www.humanexa.io/signals/taros-anda219052-for-perampanel-receives-approval-status 2026-06-18T18:30:23.425Z weekly 0.8 https://www.humanexa.io/signals/study-compares-3d-printed-vs-ready-to-wear-insoles-for-diabetic-neuropathy 2026-06-18T12:32:39.593Z weekly 0.8 https://www.humanexa.io/signals/study-reveals-mucus-plug-dynamics-in-copd-patients-and-ex-smokers 2026-06-18T12:32:28.508Z weekly 0.8 https://www.humanexa.io/signals/fda-submission-update-for-topiramate-by-aiping-pharm-inc 2026-06-18T12:32:15.790Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-application-for-yervoy-ipilimumab-by-bristol-myers-squibb 2026-06-18T12:31:53.188Z weekly 0.8 https://www.humanexa.io/signals/fda-acceptance-of-nda-for-capivasertib-by-astrazeneca 2026-06-18T12:31:43.194Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-application-for-skyrizi-risankizumab 2026-06-18T12:31:35.150Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-for-clonazepam-by-rubicon-research 2026-06-18T12:31:25.348Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-application-for-skyrizi-risankizumab-by-abbvie 2026-06-18T12:31:06.092Z weekly 0.8 https://www.humanexa.io/signals/lupins-doxycycline-anda204234-receives-ap-status-from-fda 2026-06-18T12:30:55.995Z weekly 0.8 https://www.humanexa.io/signals/alembic-submits-anda-for-bosutinib-monohydrate 2026-06-18T12:30:46.512Z weekly 0.8 https://www.humanexa.io/signals/phase-ibii-trial-of-qlc5508-and-qlh12016-in-advanced-prostate-cancer 2026-06-18T12:30:34.606Z weekly 0.8 https://www.humanexa.io/signals/study-evaluates-epro-follow-up-for-oncology-patients-post-hospitalization 2026-06-18T12:30:26.349Z weekly 0.8 https://www.humanexa.io/signals/ciplas-anda214209-for-sumatriptan-receives-abbreviated-approval-from-fda 2026-06-18T06:33:11.691Z weekly 0.8 https://www.humanexa.io/signals/fda-approval-update-for-divalproex-sodium-by-mylan 2026-06-18T06:32:57.876Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-for-absorica-ld-by-sun-pharma 2026-06-18T06:32:47.216Z weekly 0.8 https://www.humanexa.io/signals/bayers-nda219627-receives-approval-from-fda 2026-06-18T06:32:33.845Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-abbreviated-approval-for-divalproex-sodium-by-unichem 2026-06-18T06:32:21.563Z weekly 0.8 https://www.humanexa.io/signals/study-on-treatment-patterns-for-nivolumab-in-community-oncology-settings 2026-06-18T06:32:08.042Z weekly 0.8 https://www.humanexa.io/signals/phase-ii-trial-of-proton-therapy-for-craniopharyngioma-shows-feasibility-and-saf 2026-06-18T06:31:57.284Z weekly 0.8 https://www.humanexa.io/signals/study-on-de-escalation-of-radiation-therapy-in-node-negative-breast-cancer 2026-06-18T06:31:31.365Z weekly 0.8 https://www.humanexa.io/signals/act-vs-cbt-trial-for-psychological-distress-in-hivaids-patients 2026-06-18T06:31:20.795Z weekly 0.8 https://www.humanexa.io/signals/phase-ii-trial-of-olaparib-and-durvalumab-combinations-in-recurrent-endometrial- 2026-06-18T06:31:07.896Z weekly 0.8 https://www.humanexa.io/signals/phase-ii-trial-of-selumetinib-and-olaparib-in-ras-pathway-mutant-ovarian-and-end 2026-06-18T06:30:54.546Z weekly 0.8 https://www.humanexa.io/signals/phase-ii-trial-of-nivolumab-for-persistent-cervical-cancer-shows-potential-effic 2026-06-18T06:30:43.153Z weekly 0.8 https://www.humanexa.io/signals/raptor-trial-evaluates-radiation-therapy-with-atezolizumab-in-extensive-stage-sm 2026-06-18T06:30:26.200Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-approval-for-gadobutrol-anda219287-by-viwit-pharm 2026-06-18T06:04:48.072Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-approval-for-tretinoin-anda214590-by-alembic 2026-06-18T06:04:37.909Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-application-for-enspryng-satralizumab 2026-06-18T06:04:27.441Z weekly 0.8 https://www.humanexa.io/signals/study-on-endoscopic-gastric-mucosal-ablation-for-class-iii-obesity-initiated 2026-06-18T06:04:17.955Z weekly 0.8 https://www.humanexa.io/signals/genentech-initiates-study-on-progression-of-intermediate-age-related-macular-deg 2026-06-18T06:04:01.562Z weekly 0.8 https://www.humanexa.io/signals/nivolumab-phase-iii-trial-for-high-risk-stage-ii-iiib-anal-cancer-initiated 2026-06-18T06:03:36.492Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-evaluates-pembrolizumab-timing-in-nsclc-treatment 2026-06-18T06:02:43.653Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-supplemental-application-for-zyrtec-hives-by-kenvue-brands 2026-06-18T00:33:36.298Z weekly 0.8 https://www.humanexa.io/signals/hikmas-methylprednisolone-sodium-succinate-anda203125-receives-ap-status 2026-06-18T00:33:27.642Z weekly 0.8 https://www.humanexa.io/signals/apotex-inc-submits-anda-for-ruxolitinib 2026-06-18T00:32:16.164Z weekly 0.8 https://www.humanexa.io/signals/study-on-educational-intervention-for-breast-cancer-patients-adherence-and-sexua 2026-06-18T00:31:41.523Z weekly 0.8 https://www.humanexa.io/signals/dabrafenib-and-trametinib-rollover-study-for-continued-patient-access 2026-06-18T00:31:31.171Z weekly 0.8 https://www.humanexa.io/signals/phase-ii-trial-investigates-vitamin-ds-impact-on-menstrual-cycle-health 2026-06-18T00:31:20.820Z weekly 0.8 https://www.humanexa.io/signals/evolve-study-to-assess-real-world-effectiveness-of-tezepelumab-in-severe-asthma- 2026-06-18T00:31:10.950Z weekly 0.8 https://www.humanexa.io/signals/study-on-optimizing-crt-lead-placement-for-non-lbbb-patients-using-advanced-imag 2026-06-18T00:30:51.757Z weekly 0.8 https://www.humanexa.io/signals/study-on-acs-geriatric-surgery-programs-impact-on-older-cancer-patients 2026-06-18T00:30:34.916Z weekly 0.8 https://www.humanexa.io/signals/feasibility-study-on-sensory-changes-in-pediatric-oncology-patients-undergoing-t 2026-06-18T00:30:24.640Z weekly 0.8 https://www.humanexa.io/signals/fda-lists-quinacrine-hydrochloride-for-compounding-in-cutaneous-lupus-erythemato 2026-06-17T18:32:14.228Z weekly 0.8 https://www.humanexa.io/signals/robin-trial-to-explore-rt-effects-on-immune-system-in-rectal-cancer 2026-06-17T18:32:00.446Z weekly 0.8 https://www.humanexa.io/signals/study-on-early-rehabilitation-protocol-for-breast-cancer-surgery-shows-promising 2026-06-17T18:31:52.669Z weekly 0.8 https://www.humanexa.io/signals/sillajen-initiates-phase-1-trial-of-bal0891-in-advanced-solid-tumors-and-aml 2026-06-17T18:31:42.312Z weekly 0.8 https://www.humanexa.io/signals/study-on-durvalumab-bevacizumab-and-tace-for-advanced-hepatocellular-carcinoma 2026-06-17T18:31:19.548Z weekly 0.8 https://www.humanexa.io/signals/nemtabrutinib-study-vs-ibrutinibacalabrutinib-in-1l-cllsll-initiated 2026-06-17T18:31:07.632Z weekly 0.8 https://www.humanexa.io/signals/zilovertamab-vedotin-shows-promise-in-rrdlbcl-with-standard-care-in-phase-23-stu 2026-06-17T18:30:56.551Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-adipose-derived-stem-cells-for-burn-scarring-initiated-in-den 2026-06-17T18:30:45.334Z weekly 0.8 https://www.humanexa.io/signals/trial-on-s-icd-implantation-without-defibrillation-testing-shows-non-inferiority 2026-06-17T18:30:34.418Z weekly 0.8 https://www.humanexa.io/signals/r-mvst-cells-show-promise-for-treating-refractory-viral-infections 2026-06-17T18:30:25.604Z weekly 0.8 https://www.humanexa.io/signals/fda-draft-guidance-aims-to-reduce-animal-testing-for-cancer-drugs 2026-06-17T12:32:25.451Z weekly 0.8 https://www.humanexa.io/signals/study-on-psb-pacing-to-prevent-atrial-fibrillation-in-sinus-node-dysfunction-pat 2026-06-17T12:31:43.576Z weekly 0.8 https://www.humanexa.io/signals/boomerang-medical-initiates-pivotal-trial-for-device-in-ulcerative-colitis 2026-06-17T12:31:34.267Z weekly 0.8 https://www.humanexa.io/signals/phase-3-trial-of-tqb2868-and-anlotinib-in-metastatic-pancreatic-cancer-initiated 2026-06-17T12:31:23.972Z weekly 0.8 https://www.humanexa.io/signals/db-1303bnt323-trial-in-her2-low-metastatic-breast-cancer-initiated 2026-06-17T12:31:13.137Z weekly 0.8 https://www.humanexa.io/signals/study-on-exercise-programs-impact-on-quality-of-life-in-prostate-cancer-patients 2026-06-17T12:31:02.843Z weekly 0.8 https://www.humanexa.io/signals/large-study-on-breast-phyllodes-tumors-in-china-aims-to-enhance-treatment-guidel 2026-06-17T12:30:54.117Z weekly 0.8 https://www.humanexa.io/signals/phase-2-study-of-aur103-calcium-in-advanced-neuroendocrine-tumours-initiated 2026-06-17T12:30:44.707Z weekly 0.8 https://www.humanexa.io/signals/kshb002-trial-shows-equivalence-to-orencia-in-pk-safety-and-immunogenicity-for-r 2026-06-17T12:30:35.529Z weekly 0.8 https://www.humanexa.io/signals/study-evaluates-outcomes-after-discontinuation-of-btk-inhibitors-in-cll-patients 2026-06-17T12:30:25.533Z weekly 0.8 https://www.humanexa.io/signals/study-reveals-risk-factors-for-second-primary-cancer-in-colorectal-cancer-surviv 2026-06-17T06:33:22.615Z weekly 0.8 https://www.humanexa.io/signals/study-on-socio-aesthetics-care-impact-on-cancer-patients-quality-of-life 2026-06-17T06:32:29.127Z weekly 0.8 https://www.humanexa.io/signals/launch-of-alzheimers-disease-neuroimaging-initiative-4-to-validate-biomarkers 2026-06-17T06:32:17.340Z weekly 0.8 https://www.humanexa.io/signals/phase-3-trial-of-gammatile-vs-standard-care-in-gbm-surgery-initiated 2026-06-17T06:31:54.859Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-compares-6-vs-12-months-of-her2-targeted-therapy-in-breast-cance 2026-06-17T06:31:34.783Z weekly 0.8 https://www.humanexa.io/signals/analysis-reveals-key-trends-in-als-immunotherapeutics-research-and-collaboration 2026-06-17T06:04:50.928Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-hemay005-in-chinese-patients-with-ulcerative-colitis-initiate 2026-06-17T06:04:19.564Z weekly 0.8 https://www.humanexa.io/signals/trial-evaluates-pelvic-radiotherapy-with-adt-in-node-positive-prostate-cancer 2026-06-17T06:02:50.549Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-evaluates-hormone-therapy-and-chemotherapy-in-invasive-breast-ca 2026-06-17T00:31:57.981Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-evaluates-triapine-with-cisplatin-for-advanced-cervical-and-vagi 2026-06-17T00:31:48.790Z weekly 0.8 https://www.humanexa.io/signals/phase-ii-trial-compares-folfox8-and-mfolfox6-in-metastatic-colorectal-cancer 2026-06-17T00:31:30.954Z weekly 0.8 https://www.humanexa.io/signals/astrazeneca-reports-strong-q1-2026-revenue-growth-and-positive-nme-readouts 2026-06-16T18:31:32.574Z weekly 0.8 https://www.humanexa.io/signals/merck-acknowledges-daiichi-sankyos-adc-manufacturing-update 2026-06-16T18:31:23.032Z weekly 0.8 https://www.humanexa.io/signals/roche-to-present-phase-ii-data-on-enicepatide-and-petrelintide-at-ada-2026-1 2026-06-16T18:31:02.941Z weekly 0.8 https://www.humanexa.io/signals/roche-to-present-phase-ii-data-on-enicepatide-and-petrelintide-at-ada-2026 2026-06-16T12:32:01.874Z weekly 0.8 https://www.humanexa.io/signals/fda-extends-decision-date-for-astrazenecas-camizestrant-in-hr-positive-breast-ca 2026-06-16T06:34:14.993Z weekly 0.8 https://www.humanexa.io/signals/non-coding-rnas-as-regulators-of-aerobic-glycolysis-in-pancreatic-ductal-adenoca 2026-06-15T18:00:37.814Z weekly 0.8 https://www.humanexa.io/signals/phase-3-trial-of-maridebart-cafraglutide-in-obstructive-sleep-apnea-patients 2026-06-15T11:55:18.163Z weekly 0.8 https://www.humanexa.io/signals/phase-3-study-of-duvakitug-for-moderately-to-severely-active-ulcerative-colitis- 2026-06-15T11:55:08.806Z weekly 0.8 https://www.humanexa.io/signals/lillys-zepbound-tirzepatide-targets-moderate-obstructive-sleep-apnea-in-national 2026-06-15T11:54:58.429Z weekly 0.8 https://www.humanexa.io/signals/gsks-as03-adjuvanted-h5n8-vaccine-shows-promising-immunogenicity-and-safety-in-p 2026-06-14T12:00:17.411Z weekly 0.8 https://www.humanexa.io/signals/new-biobank-established-for-cutaneous-melanoma-and-non-melanoma-research 2026-06-14T00:01:10.724Z weekly 0.8 https://www.humanexa.io/signals/study-on-ultrasound-guidance-for-central-catheterization-in-obese-icu-patients 2026-06-13T18:00:15.311Z weekly 0.8 https://www.humanexa.io/signals/covac-2-vaccine-shows-safety-and-immunogenicity-as-covid-19-booster-in-phase-1-t 2026-06-13T12:00:56.818Z weekly 0.8 https://www.humanexa.io/signals/phase-ii-trial-of-sal0140-shows-promise-for-primary-aldosteronism 2026-06-13T12:00:34.132Z weekly 0.8 https://www.humanexa.io/signals/trial-on-mri-guided-sbrt-for-liver-metastases-aims-to-establish-safe-dose-levels 2026-06-13T06:00:18.545Z weekly 0.8 https://www.humanexa.io/signals/mri-guided-radiotherapy-trial-for-hpv-positive-oropharyngeal-cancer-initiated 2026-06-12T18:00:57.390Z weekly 0.8 https://www.humanexa.io/signals/surufatinib-trial-initiated-for-adjuvant-therapy-in-pancreatic-neuroendocrine-tu 2026-06-12T12:01:33.824Z weekly 0.8 https://www.humanexa.io/signals/phase-iiia-trial-of-mc1r-targeted-therapy-with-nivolumab-in-advanced-melanoma 2026-06-12T06:00:42.581Z weekly 0.8 https://www.humanexa.io/signals/trial-compares-silicone-barrier-spray-to-zinc-oxide-for-incontinence-associated- 2026-06-12T00:00:49.822Z weekly 0.8 https://www.humanexa.io/signals/dapagliflozin-vs-metformin-for-antipsychotic-induced-weight-gain-in-clinical-tri 2026-06-11T18:02:04.334Z weekly 0.8 https://www.humanexa.io/signals/clinical-trial-evaluates-prs-ck-storm-for-cytokine-storm-in-respiratory-infectio 2026-06-11T18:01:55.329Z weekly 0.8 https://www.humanexa.io/signals/4cmenb-and-menacwy-crm-vaccines-co-administered-safely-in-adolescents 2026-06-11T12:01:42.641Z weekly 0.8 https://www.humanexa.io/signals/study-on-timing-of-midazolam-in-pediatric-adenotonsillectomy-to-assess-stress-an 2026-06-11T12:01:30.729Z weekly 0.8 https://www.humanexa.io/signals/trial-of-cxd-and-ketogenic-diet-for-masld-shows-structured-approach 2026-06-11T12:01:21.546Z weekly 0.8 https://www.humanexa.io/signals/trial-comparing-behavioral-activation-to-relapse-prevention-for-veterans-with-au 2026-06-11T06:01:28.210Z weekly 0.8 https://www.humanexa.io/signals/pilot-trial-of-digitally-enhanced-stepped-care-for-depression-in-primary-care-in 2026-06-11T00:02:01.609Z weekly 0.8 https://www.humanexa.io/signals/study-on-image-guided-cancer-treatments-using-spectral-angio-ct 2026-06-11T00:01:50.076Z weekly 0.8 https://www.humanexa.io/signals/ai-driven-nutrition-study-for-type-2-diabetes-shows-promise-for-glycemic-control 2026-06-10T18:00:41.446Z weekly 0.8 https://www.humanexa.io/signals/study-compares-pe-therapy-pharmacotherapy-and-combination-for-ptsd-in-veterans 2026-06-10T12:01:05.430Z weekly 0.8 https://www.humanexa.io/signals/phase-ii-trial-of-venetoclax-and-rituximab-in-older-patients-with-mantle-cell-ly 2026-06-10T12:00:52.749Z weekly 0.8 https://www.humanexa.io/signals/torrents-lurasidone-hydrochloride-anda-receives-ap-status-from-fda 2026-06-10T06:00:25.356Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-for-spravato-esketamine-hydrochloride 2026-06-10T06:00:15.823Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-application-for-artesunate-by-amivas 2026-06-10T00:01:51.882Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-for-filspari-sparsentan-by-travere 2026-06-10T00:01:41.400Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-approval-for-pimozide-anda219897-by-novitium-pharma 2026-06-09T18:00:49.515Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-approval-for-olmesartan-medoxomil-and-hydrochlorothiazide-anda206371 2026-06-09T18:00:39.768Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplemental-application-for-concerta-by-janssen 2026-06-09T12:00:32.833Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-ap-status-for-lidocaine-hydrochloride-04-in-dextrose-5 2026-06-09T12:00:21.418Z weekly 0.8 https://www.humanexa.io/signals/fda-approval-status-update-for-lidocaine-hydrochloride-04-in-dextrose-5 2026-06-09T06:00:23.567Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-ap-status-for-diltiazem-hydrochloride-anda216327 2026-06-09T00:00:14.930Z weekly 0.8 https://www.humanexa.io/signals/fda-approval-process-update-for-mycophenolate-mofetil-by-strides-pharma 2026-06-08T18:01:07.009Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-supplement-for-methylprednisolone-acetate-by-sandoz 2026-06-08T12:01:09.205Z weekly 0.8 https://www.humanexa.io/signals/sandozs-methylprednisolone-anda040194-receives-ap-status-from-fda 2026-06-08T00:00:20.306Z weekly 0.8 https://www.humanexa.io/signals/glenmark-pharmaceuticals-submits-supplemental-application-for-lamotrigine 2026-06-07T18:00:33.652Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-ap-status-for-doxycycline-hyclate-supplement-by-impax-labs 2026-06-07T12:00:23.605Z weekly 0.8 https://www.humanexa.io/signals/south-african-hcps-support-dual-prevention-pill-but-highlight-key-challenges 2026-06-07T06:01:43.998Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-ap-status-for-mesna-anda203364-submission-by-rising 2026-06-07T06:01:36.684Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-for-vabysmo-by-genentech 2026-06-07T06:01:28.328Z weekly 0.8 https://www.humanexa.io/signals/fda-approval-status-update-for-losartan-potassium-by-micro-labs 2026-06-07T00:00:24.901Z weekly 0.8 https://www.humanexa.io/signals/alembics-duloxetine-hydrochloride-supplement-receives-ap-status-from-fda 2026-06-07T00:00:16.620Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-deflazacort-supplement-application-by-upsher-smith-labs 2026-06-06T18:00:40.324Z weekly 0.8 https://www.humanexa.io/signals/aurobindo-pharmas-lamotrigine-anda-submission-receives-ap-status 2026-06-06T18:00:31.331Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-supplement-for-levetiracetam-by-chartwell-rx 2026-06-06T12:01:41.453Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-application-for-cosopt-pf-supplement-by-thea-pharma 2026-06-06T12:01:32.591Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-approval-for-phenylephrine-hydrochloride-by-baxter-healthcare 2026-06-06T06:00:47.187Z weekly 0.8 https://www.humanexa.io/signals/fda-submission-update-for-ondansetron-hydrochloride-anda078127 2026-06-06T06:00:35.737Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-application-for-tyvaso-treprostinil 2026-06-06T00:00:51.990Z weekly 0.8 https://www.humanexa.io/signals/fda-submission-for-dapagliflozin-by-jiangsu-hansoh-pharma 2026-06-06T00:00:40.603Z weekly 0.8 https://www.humanexa.io/signals/study-on-resistance-trainings-impact-on-womens-health-during-menopause 2026-06-19T06:31:04.692Z weekly 0.8 https://www.humanexa.io/signals/alembic-pharmaceuticals-submits-anda220639-for-review 2026-06-18T00:32:24.355Z weekly 0.8 https://www.humanexa.io/signals/teva-pharmaceuticals-submits-anda219413-for-fda-review 2026-06-18T00:32:05.670Z weekly 0.8 https://www.humanexa.io/signals/comparative-study-of-spsipb-vs-thoracic-paravertebral-block-for-opioid-reduction 2026-06-02T03:09:28.046Z weekly 0.8 https://www.humanexa.io/signals/pilot-study-on-geniculate-artery-embolization-for-knee-osteoarthritis-initiated 2026-06-02T03:09:23.745Z weekly 0.8 https://www.humanexa.io/signals/imfinziimjudo-shows-significant-pfs-improvement-in-early-liver-cancer-trial 2026-06-02T03:09:20.953Z weekly 0.8 https://www.humanexa.io/signals/efzimfotase-alfa-shows-positive-phase-iii-results-in-hypophosphatasia 2026-06-02T03:09:15.835Z weekly 0.8 https://www.humanexa.io/signals/trial-on-pulmonary-artery-catheters-in-cardiac-surgery-aims-to-compare-recovery- 2026-06-02T03:01:35.313Z weekly 0.8 https://www.humanexa.io/signals/tapur-study-evaluates-targeted-therapies-in-advanced-cancer-with-genomic-variant 2026-06-02T03:01:32.508Z weekly 0.8 https://www.humanexa.io/signals/tozorakimab-achieves-primary-endpoints-in-phase-iii-trials-for-copd 2026-06-02T03:01:29.578Z weekly 0.8 https://www.humanexa.io/signals/enhertu-recommended-for-eu-approval-in-her2-metastatic-solid-tumours 2026-06-02T03:01:25.861Z weekly 0.8 https://www.humanexa.io/signals/zhuochuming-trial-evaluates-3te-vs-3prn-in-diabetic-macular-edema 2026-06-01T19:50:47.438Z weekly 0.8 https://www.humanexa.io/signals/study-on-nmes-for-functional-recovery-in-copd-and-pneumonia-patients 2026-06-01T19:50:43.736Z weekly 0.8 https://www.humanexa.io/signals/fda-issues-guidance-on-postapproval-pregnancy-safety-studies 2026-06-01T19:50:38.722Z weekly 0.8 https://www.humanexa.io/signals/astrazenecas-baxfendy-receives-us-approval-for-hypertension-as-first-in-class-tr 2026-06-01T19:50:35.739Z weekly 0.8 https://www.humanexa.io/signals/breztri-gains-us-approval-as-first-triple-therapy-for-asthma 2026-06-01T19:50:32.737Z weekly 0.8 https://www.humanexa.io/companies/roche 2026-06-16T18:31:42.702Z weekly 0.82 https://www.humanexa.io/companies/merck 2026-06-17T06:02:41.035Z weekly 0.82 https://www.humanexa.io/companies/astrazeneca 2026-06-16T18:31:42.702Z weekly 0.82 https://www.humanexa.io/companies/pfizer 2026-06-17T00:30:23.482Z weekly 0.82 https://www.humanexa.io/companies/lilly 2026-06-17T12:31:53.003Z weekly 0.82 https://www.humanexa.io/companies/bristolmyerssquibb 2026-06-17T06:34:03.216Z weekly 0.82 https://www.humanexa.io/companies/janssenpharmaceuticals 2026-06-16T12:30:48.590Z weekly 0.82 https://www.humanexa.io/companies/abbvie 2026-06-18T12:31:06.092Z weekly 0.82 https://www.humanexa.io/companies/novartis 2026-06-17T06:33:48.630Z weekly 0.82 https://www.humanexa.io/companies/stridespharma 2026-06-17T06:01:58.624Z weekly 0.82 https://www.humanexa.io/companies/gsk 2026-06-17T12:31:53.003Z weekly 0.82 https://www.humanexa.io/companies/novitiumpharma 2026-06-18T18:30:31.293Z weekly 0.82 https://www.humanexa.io/companies/regeneron 2026-06-16T18:32:12.027Z weekly 0.82 https://www.humanexa.io/companies/amgen 2026-06-16T18:32:38.060Z weekly 0.82 https://www.humanexa.io/companies/moderna 2026-06-17T06:32:59.505Z weekly 0.82 https://www.humanexa.io/companies/alembicpharmaceuticals 2026-06-18T12:30:46.512Z weekly 0.82 https://www.humanexa.io/companies/biogen 2026-06-17T06:04:50.928Z weekly 0.82 https://www.humanexa.io/companies/sciegenpharmaceuticals 2026-06-07T00:00:24.901Z weekly 0.82 https://www.humanexa.io/companies/unitedtherapeutics 2026-06-17T06:03:28.190Z weekly 0.82 https://www.humanexa.io/companies/gilead 2026-06-16T06:31:41.775Z weekly 0.82 https://www.humanexa.io/companies/novonordisk 2026-06-17T18:32:32.154Z weekly 0.82 https://www.humanexa.io/companies/bayer 2026-06-17T06:33:35.927Z weekly 0.82 https://www.humanexa.io/companies/alexion 2026-06-02T03:09:15.835Z weekly 0.82 https://www.humanexa.io/companies/takeda 2026-06-19T06:01:53.724Z weekly 0.82 https://www.humanexa.io/companies/daiichisankyo 2026-06-17T06:30:25.574Z weekly 0.82 https://www.humanexa.io/companies/qlcbiotech 2026-06-18T12:30:34.606Z weekly 0.82 https://www.humanexa.io/companies/travere 2026-06-10T00:01:41.400Z weekly 0.82 https://www.humanexa.io/companies/syhapharmaceuticals 2026-06-17T06:03:39.485Z weekly 0.82 https://www.humanexa.io/companies/dbpharma 2026-06-17T12:31:13.137Z weekly 0.82 https://www.humanexa.io/companies/ganzhouhemaypharmaceutical 2026-06-17T06:04:19.564Z weekly 0.82 https://www.humanexa.io/companies/theapharma 2026-06-06T12:01:32.591Z weekly 0.82 https://www.humanexa.io/companies/acadiapharmaceuticals 2026-06-17T06:03:48.692Z weekly 0.82 https://www.humanexa.io/companies/amphastarpharmaceuticals 2026-06-18T18:30:40.003Z weekly 0.82 https://www.humanexa.io/companies/sandoz 2026-06-08T12:01:09.205Z weekly 0.82 https://www.humanexa.io/companies/decipherapharmaceuticalsllc 2026-06-18T18:31:30.133Z weekly 0.82 https://www.humanexa.io/companies/taropharmaceuticals 2026-06-18T18:30:23.425Z weekly 0.82 https://www.humanexa.io/companies/cipla 2026-06-18T06:33:11.691Z weekly 0.82 https://www.humanexa.io/companies/tqbbiopharma 2026-06-17T12:31:23.972Z weekly 0.82 https://www.humanexa.io/companies/kshbbiopharma 2026-06-17T12:30:35.529Z weekly 0.82 https://www.humanexa.io/companies/torrentpharmaceuticals 2026-06-10T06:00:25.356Z weekly 0.82 https://www.humanexa.io/companies/incyte 2026-06-18T00:32:16.164Z weekly 0.82 https://www.humanexa.io/companies/glenmarkpharmaceuticals 2026-06-07T18:00:33.652Z weekly 0.82 https://www.humanexa.io/companies/bayerhealthcarepharmaceuticals 2026-06-18T06:32:33.845Z weekly 0.82 https://www.humanexa.io/companies/lupinpharmaceuticals 2026-06-18T12:30:55.995Z weekly 0.82 https://www.humanexa.io/companies/mylan 2026-06-18T06:32:57.876Z weekly 0.82 https://www.humanexa.io/companies/hikmapharmaceuticals 2026-06-18T00:33:27.642Z weekly 0.82 https://www.humanexa.io/companies/jiangsuhansohpharma 2026-06-06T00:00:40.603Z weekly 0.82 https://www.humanexa.io/companies/sunpharma 2026-06-18T06:32:47.216Z weekly 0.82 https://www.humanexa.io/companies/tevapharmaceuticals 2026-06-18T00:32:05.670Z weekly 0.82 https://www.humanexa.io/companies/aurobindopharma 2026-06-06T18:00:31.331Z weekly 0.82 https://www.humanexa.io/companies/roche/assets/regulatory-acceptance-of-cosopt-pf-signals-competitive-shift-in-glaucoma-market 2026-06-07T06:01:37.909Z weekly 0.84 https://www.humanexa.io/companies/merck/assets/regulatory-developments-in-oncology-competitive-landscape-and-strategic-implicat 2026-06-19T08:02:42.428Z weekly 0.84 https://www.humanexa.io/companies/astrazeneca/assets/emerging-combination-therapies-and-targeted-approaches-in-liver-cancer-treatment 2026-06-19T10:00:38.397Z weekly 0.84 https://www.humanexa.io/companies/astrazeneca/assets/enhertus-eu-approval-could-redefine-her2-treatment-landscape 2026-06-16T06:35:04.106Z weekly 0.84 https://www.humanexa.io/companies/astrazeneca/assets/positive-phase-iii-results-for-efzimfotase-alfa-reshape-hypophosphatasia-landsca 2026-06-03T01:14:22.460Z weekly 0.84 https://www.humanexa.io/companies/astrazeneca/assets/emerging-therapeutics-in-copd-tozorakimab-and-nmes-trials-signal-strategic-shift 2026-06-06T14:54:00.106Z weekly 0.84 https://www.humanexa.io/companies/astrazeneca/assets/astrazenecas-baxfendy-approval-a-strategic-shift-in-hypertension-treatment 2026-06-11T09:12:14.605Z weekly 0.84 https://www.humanexa.io/companies/astrazeneca/assets/breztris-unique-positioning-as-first-triple-therapy-in-asthma-market 2026-06-03T01:14:21.674Z weekly 0.84 https://www.humanexa.io/companies/pfizer/assets/pfizers-hympavzi-approval-enhances-pediatric-hemophilia-treatment-landscape 2026-06-16T22:58:39.488Z weekly 0.84 https://www.humanexa.io/companies/lilly/assets/eli-lillys-aj1-11095-phase-1-data-enhances-competitive-position-in-myelofibrosis 2026-06-19T08:25:09.650Z weekly 0.84 https://www.humanexa.io/companies/lilly/assets/eli-lillys-retatrutide-emerges-as-a-game-changer-in-obesity-treatment-landscape 2026-06-16T22:58:41.041Z weekly 0.84 https://www.humanexa.io/companies/lilly/assets/lillys-zepbound-launch-strategic-positioning-in-obstructive-sleep-apnea-market 2026-06-15T11:55:20.853Z weekly 0.84 https://www.humanexa.io/companies/janssenpharmaceuticals/assets/regulatory-approvals-reshape-competitive-landscape-in-neurology-markets 2026-06-18T18:31:57.401Z weekly 0.84 https://www.humanexa.io/companies/stridespharma/assets/regulatory-developments-reshape-competitive-landscape-in-immunology-market 2026-06-18T12:32:37.079Z weekly 0.84 https://www.humanexa.io/companies/novitiumpharma/assets/aurobindo-pharmas-lamotrigine-approval-signals-market-disruption-in-antiepilepti 2026-06-18T18:31:27.225Z weekly 0.84 https://www.humanexa.io/companies/sciegenpharmaceuticals/assets/baxters-phenylephrine-approval-reshapes-vasopressor-market-dynamics 2026-06-10T04:54:09.378Z weekly 0.84 https://www.humanexa.io/companies/unitedtherapeutics/assets/regulatory-developments-enhance-competitive-landscape-for-tyvaso-in-pah-market 2026-06-06T08:00:21.796Z weekly 0.84 https://www.humanexa.io/companies/travere/assets/regulatory-milestone-for-traveres-filspari-enhances-competitive-positioning 2026-06-10T00:01:50.614Z weekly 0.84 https://www.humanexa.io/companies/torrentpharmaceuticals/assets/torrent-pharmaceuticals-gains-competitive-edge-with-lurasidone-hydrochloride-app 2026-06-10T06:00:36.878Z weekly 0.84 https://www.humanexa.io/companies/jiangsuhansohpharma/assets/jiangsu-hansohs-dapagliflozin-submission-intensifies-sglt2-inhibitor-competition 2026-06-06T08:00:28.047Z weekly 0.84 https://www.humanexa.io/newsletter/3f84cd5a-99c2-49b3-b890-09f98fbce08c 2026-06-06T06:47:03.383Z monthly 0.75